使用V-Go可穿戴胰岛素给药装置对2型糖尿病患者临床结局的评估。
Evaluation of Clinical Outcomes With the V-Go Wearable Insulin Delivery Device in Patients With Type 2 Diabetes.
作者信息
Meade Lisa T, Battise Dawn
机构信息
Wingate University, Hickory, NC.
Catawba Valley Health System, Hickory, NC.
出版信息
Clin Diabetes. 2021 Jul;39(3):297-303. doi: 10.2337/cd20-0094.
Abstract
Uncontrolled type 2 diabetes can lead to a multitude of health complications. Insulin therapy is recommended when patients are unable to reach their A1C goal with oral or noninsulin injectable diabetes medications. This study evaluated the clinical benefits of switching from multiple daily insulin injections to a wearable insulin delivery device (V-Go). A retrospective chart review was conducted on 44 patients who received prescriptions for the V-Go at two family medicine offices. Investigators found a significant reduction in A1C and daily insulin requirements with no impact on weight or BMI.
摘要
未控制的2型糖尿病会导致多种健康并发症。当患者使用口服或非胰岛素注射类糖尿病药物无法达到糖化血红蛋白（A1C）目标时，建议进行胰岛素治疗。本研究评估了从每日多次胰岛素注射转换为可穿戴胰岛素输送装置（V-Go）的临床益处。对在两家家庭医学诊所开具了V-Go处方的44名患者进行了回顾性病历审查。研究人员发现，糖化血红蛋白和每日胰岛素需求量显著降低，对体重或体重指数没有影响。
相似文献
1
Evaluation of Clinical Outcomes With the V-Go Wearable Insulin Delivery Device in Patients With Type 2 Diabetes.
Clin Diabetes. 2021 Jul;39(3):297-303. doi: 10.2337/cd20-0094.
2
Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis.
Pharmacy (Basel). 2020 Nov 14;8(4):215. doi: 10.3390/pharmacy8040215.
3
Multicenter Real-World Assessment of the Effectiveness of V-Go Wearable Insulin Delivery Device in Adult Patients with Type 2 Diabetes (ENABLE Study): A Retrospective Analysis.
Med Devices (Auckl). 2020 Sep 22;13:283-291. doi: 10.2147/MDER.S265869. eCollection 2020.
4
CLINICAL AND COST-EFFECTIVENESS OF INSULIN DELIVERY WITH V-GO(®) DISPOSABLE INSULIN DELIVERY DEVICE VERSUS MULTIPLE DAILY INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN.
Endocr Pract. 2016 Jun;22(6):726-35. doi: 10.4158/EP151182.OR. Epub 2016 Feb 1.
5
The Clinical and Economic Impact of the V-Go Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk.
Drugs Real World Outcomes. 2016 Jun 2;3(2):191-199. doi: 10.1007/s40801-016-0075-4. eCollection 2016 Jun.
6
V-Go Insulin Delivery System Versus Multiple Daily Insulin Injections for Patients With Uncontrolled Type 2 Diabetes Mellitus.
J Diabetes Sci Technol. 2015 Apr 21;9(5):1111-6. doi: 10.1177/1932296815580361.
7
Clinical and economic considerations based on persistency with a novel insulin delivery device versus conventional insulin delivery in patients with type 2 diabetes: A retrospective analysis.
Res Social Adm Pharm. 2019 Sep;15(9):1126-1132. doi: 10.1016/j.sapharm.2018.09.016. Epub 2018 Sep 26.
8
Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes.
BMJ Open Diabetes Res Care. 2020 Nov;8(2). doi: 10.1136/bmjdrc-2020-001832.
9
Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Endocr Pract. 2018 Sep;24(9):805-814. doi: 10.4158/EP-2017-0261. Epub 2018 Jul 5.
10
Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure.
Pharmacotherapy. 2016 Dec;36(12):1210-1216. doi: 10.1002/phar.1853. Epub 2016 Nov 28.
引用本文的文献
1
Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions.
Pharmaceutics. 2024 Jul 15;16(7):944. doi: 10.3390/pharmaceutics16070944.
本文引用的文献
1
A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes.
J Health Econ Outcomes Res. 2019 Mar 27;6(2):70-83. doi: 10.36469/9731. eCollection 2019.
2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - .
Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.
3
9. Pharmacologic Approaches to Glycemic Treatment: .
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
4
7. Diabetes Technology: .
Diabetes Care. 2020 Jan;43(Suppl 1):S77-S88. doi: 10.2337/dc20-S007.
5
1. Improving Care and Promoting Health in Populations: -.
Diabetes Care. 2020 Jan;43(Suppl 1):S7-S13. doi: 10.2337/dc20-S001.
6
Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
J Manag Care Spec Pharm. 2019 Oct;25(10):1111-1123. doi: 10.18553/jmcp.2019.25.10.1111.
7
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions.
J Am Board Fam Med. 2019 May-Jun;32(3):431-447. doi: 10.3122/jabfm.2019.03.180162.
8
Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients.
Diabetes Ther. 2018 Oct;9(5):1931-1944. doi: 10.1007/s13300-018-0487-0. Epub 2018 Aug 17.
9
Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis.
Adv Ther. 2018 May;35(5):631-643. doi: 10.1007/s12325-018-0703-3. Epub 2018 May 10.
10
Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
J Manag Care Spec Pharm. 2018 Apr;24(4):390-400. doi: 10.18553/jmcp.2017.17218. Epub 2017 Nov 16.
Zotero 插件